Lupin in alliance with Concord Biotech announced that it has received approval from the United States Food and Drug Administration (USFDA)
for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, to market the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
